Azurity Company Profile
What is the competitive landscape for AZURITY
AZURITY has sixty approved drugs.
There are one hundred and seventy US patents protecting AZURITY drugs. There are three tentative approvals on AZURITY drugs.
Summary for Azurity
| US Patents: | 170 |
| Tradenames: | 63 |
| Ingredients: | 54 |
| NDAs: | 60 |
| Patent Litigation for Azurity: | See patent lawsuits for Azurity |
| PTAB Cases with Azurity as petitioner: | See PTAB cases with Azurity as petitioner |
Drugs and US Patents for Azurity
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | QBRELIS | lisinopril | SOLUTION;ORAL | 208401-001 | Jul 29, 2016 | AA | RX | Yes | Yes | 9,616,096 | ⤷ Start Trial | ⤷ Start Trial | |||
| Azurity | QBRELIS | lisinopril | SOLUTION;ORAL | 208401-001 | Jul 29, 2016 | AA | RX | Yes | Yes | 12,433,931 | ⤷ Start Trial | ⤷ Start Trial | |||
| Azurity | XATMEP | methotrexate sodium | SOLUTION;ORAL | 208400-001 | Apr 25, 2017 | RX | Yes | Yes | 9,855,215 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Azurity | DANZITEN | nilotinib tartrate | TABLET;ORAL | 219293-002 | Nov 7, 2024 | RX | Yes | Yes | 12,403,140 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Azurity | WIDAPLIK | amlodipine besylate; indapamide; telmisartan | TABLET;ORAL | 219423-002 | Jun 5, 2025 | DISCN | Yes | No | 12,465,599 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Azurity | SOTYLIZE | sotalol hydrochloride | SOLUTION;ORAL | 205108-001 | Oct 22, 2014 | RX | Yes | Yes | 11,013,703 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Azurity
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Azurity | ALVESCO | ciclesonide | AEROSOL, METERED;INHALATION | 021658-002 | Jan 10, 2008 | 6,036,942 | ⤷ Start Trial |
| Azurity | FERAHEME | ferumoxytol | SOLUTION;INTRAVENOUS | 022180-001 | Jun 30, 2009 | 7,553,479 | ⤷ Start Trial |
| Azurity | TUDORZA PRESSAIR | aclidinium bromide | POWDER, METERED;INHALATION | 202450-001 | Jul 23, 2012 | 9,333,195 | ⤷ Start Trial |
| Azurity | FERAHEME | ferumoxytol | SOLUTION;INTRAVENOUS | 022180-001 | Jun 30, 2009 | 8,591,864 | ⤷ Start Trial |
| Azurity | EDARBI | azilsartan kamedoxomil | TABLET;ORAL | 200796-001 | Feb 25, 2011 | 5,583,141 | ⤷ Start Trial |
| Azurity | VERELAN PM | verapamil hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020943-001 | Nov 25, 1998 | 4,863,742 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for AZURITY drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Nasal Spray | 250 mcg | ➤ Subscribe | 2012-02-13 |
| ➤ Subscribe | Extended-release Tablets | 20 mg and 30 mg | ➤ Subscribe | 2007-11-07 |
| ➤ Subscribe | Extended-release Tablets | 40 mg | ➤ Subscribe | 2007-06-11 |
| ➤ Subscribe | Extended-release Tablets | 300 mg | ➤ Subscribe | 2006-05-19 |
| ➤ Subscribe | Injection | 30 mg/mL, 17 mL single-use vials | ➤ Subscribe | 2015-12-04 |
| ➤ Subscribe | Oral Solution | 17.5 g/3.13 g/1.6 g per bottle | ➤ Subscribe | 2010-11-08 |
| ➤ Subscribe | Extended-release Tablets | 8 mg/90 mg | ➤ Subscribe | 2015-03-12 |
| ➤ Subscribe | Extended-release Tablets | 25.5 mg and 34 mg | ➤ Subscribe | 2008-11-28 |
| ➤ Subscribe | Extended-release Tablets | 8.5 mg and 17 mg | ➤ Subscribe | 2009-03-02 |
| ➤ Subscribe | Extended-release Tablets | 100 mg and 200 mg | ➤ Subscribe | 2006-07-20 |
| ➤ Subscribe | Powder for Oral Solution | 1 mg/mL | ➤ Subscribe | 2016-06-21 |
| ➤ Subscribe | Oral Solution | 1 mg/mL | ➤ Subscribe | 2018-08-31 |
International Patents for Azurity Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| United Kingdom | 2435835 | ⤷ Start Trial |
| European Patent Office | 2100599 | ⤷ Start Trial |
| Canada | 2732018 | ⤷ Start Trial |
| Lithuania | 2164467 | ⤷ Start Trial |
| Australia | 2018203271 | ⤷ Start Trial |
| Brazil | 112019015368 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Azurity Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0984957 | C300517 | Netherlands | ⤷ Start Trial | PRODUCT NAME: ACETYLSALICYLZUUR EN ESOMEPRAZOLMAGNESIUMTRIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 107516 20110912; FIRST REGISTRATION: 540235954023675402375 2011120812 |
| 1412357 | 300287 | Netherlands | ⤷ Start Trial | PRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER SITAGLIPTINE FOSFAAT MONOHYDRAAT; REGISTRATION NO/DATE: EU/1/07/383/001-018 20070323 |
| 0678503 | C300499 | Netherlands | ⤷ Start Trial | PRODUCT NAME: COMBINATIE OMVATTEND ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110114 |
| 1411900 | 122012000052 | Germany | ⤷ Start Trial | PRODUCT NAME: NAPROXEN MIT ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105 |
| 2316456 | SPC/GB17/078 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE.; REGISTERED: UK EU/1/14/988 20150330; UK PLGB 50742/0001 20150330 |
| 0748320 | 08C0019 | France | ⤷ Start Trial | PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
